Thus, presentation of a pathogen-derived epitopeby an MHC-I molecule will most often result in the activation andexpansion of specific CD8+ T cell clones, which ultimatelyshould lead to the destruction of infected target cells by activatedcytotoxic CD8+ T lymphocytes (CTLs).3−5 Furthermore,recent developments in mass spectrometry have significantly enhancedour capacity to unambiguously identify MHC-I- and MHC-II-restrictedtumor-associated antigens (TAAs) and have thus opened new avenuesfor cancer treatment.6−8. Here, CD8A is linked to cancer.